Horse tranquilliser trial is awarded $750,000 grant for Parkinson’s research

News

Author: Simge Eva DoganPublished: 26 July 2018

Prep: Cook: Serves:

Researchers at the University of Arizona College of Medicine, Tucson, US, will be trialling ketamine – a recreational drug previously used to medicate people with depression – as a treatment for Parkinson’s.

The research – led by Dr Scott Sherman – is being supported with a three-year grant of $750,000 from the Arizona Biomedical Research Commission.

The initial clinical trial will test the effect of ketamine for treating dyskinesia in 10 patients. In addition, the researchers will carry out a separate rodent study to examine how the drug affects the brain.

Dr Scott Sherman, a neurologist at the University of Arizona College of Medicine, said: “Ketamine has been long overlooked. Now it could prove very useful for Parkinson’s patients.”

For information on the latest Parkinson’s research please visit the European Parkinson’s Disease Association website.

For more information on this article click here.

Last Month

Next Month

Go Back

Share this story

Comments

Health & Fitness

3 steps to better posture for people with Parkinson’s

Improve your posture in three simple steps

“Even Muhammad Ali had a learning curve”

Maryum Ali discusses her father’s Parkinson’s disease

Download the Parkinson’s app endorsed by José Mourinho

i-PROGNOSIS helps Parkinson's outcomes via patient data logging

Is sleepwalking linked to risk of Parkinson’s disease in men?

Men who sleepwalk may be at a greater risk of developing Parkinson’s disease, according to a new study from researchers in the US. The team assessed Mayo Clinic sleep questionnaire survey answers from 25,694 men, 1% of whom had been diagnosed with Parkinson’s disease. They found that men who experienced sleepwalking were four times more likely to have Parkinson’s, and those with probable REM sleep behaviour disorder – a condition where sleepers experience sudden body movements while dreaming – were six times more likely. For those who experienced both sleepwalking and REM sleep behaviour disorder, the risk increased to eight times more likely. “We need further studies to understand this,” said senior author, Dr Xiang Gao. “Particularly to see whether sleepwalking occurs before Parkinson’s onset, and the number of individuals with sleepwalking who eventually develop Parkinson’s and other neurodegenerative diseases.”

Stay tuned for series two of the Parkinson’s Life podcast

The award-winning Parkinson’s Life podcast is back this month. Helping to amplify the voices of the international Parkinson’s community, the podcast has so far reached more than 12,000 people around the world. Thanks to the support of pharmaceutical companies, and the backing of a grant from the Boston Scientific Foundation Europe, the second series will bring together people with Parkinson’s disease and experts in their field to explore topics such as sleep hygiene, exercise and mental health, and to offer advice to listeners. Sandrine Bazile, president of the Boston Scientific Foundation Europe, says: “We fully support this project because it mirrors perfectly our mission to improve patient wellbeing using innovative solutions. We believe in the importance of the [Parkinson’s Life] podcast series, with its aim to improve the information and education available to people with Parkinson’s and their families – to help them live life to the full.”

How Parkinson’s disease could impact the way you see art

A new study from a team at the University of Pennsylvania’s Perelman School of Medicine, US, has indicated that Parkinson’s disease could affect the way people experience art. The researchers asked 43 people with the condition and 40 controls to make judgements about 10 paintings by American artist Jackson Pollock and 10 by Dutch painter Piet Mondrian, rating them according to factors including liking, beauty, motion, complexity and colour-saturation. The participants with Parkinson’s showed more of a preference for ‘high-motion’ art. They also showed a lower recognition of movement compared to controls, suggesting that the brain’s motor system may help interpret movement from static visual cues. However, the research team noted that many of the participants were on their usual medication, and that the impact of dopamine agonists on the experience of art would also need to be considered.

All fields required

First name*
Last name*
Email address*
Enter Email Confirm Email
Country of residence*
About me*
- I have Parkinson's disease
- I am a partner / carer / family / friend of someone who has Parkinson's
- I am a healthcare professional with an interest in Parkinson's
- I work for a Parkinson's disease organisation
- Other
CAPTCHA
*
- By proceeding you agree to our
Name
This field is for validation purposes and should be left unchanged.

Horse tranquilliser trial is awarded $750,000 grant for Parkinson’s research

News

Author: Simge Eva DoganPublished: 26 July 2018

Prep: Cook: Serves:

Last Month

Next Month

Share this story

Comments

Health & Fitness

3 steps to better posture for people with Parkinson’s

Interviews

“Even Muhammad Ali had a learning curve”

PD in Practice

Download the Parkinson’s app endorsed by José Mourinho

Is sleepwalking linked to risk of Parkinson’s disease in men?

Stay tuned for series two of the Parkinson’s Life podcast

How Parkinson’s disease could impact the way you see art

{title}

Subscribe

Horse tranquilliser trial is awarded $750,000 grant for Parkinson’s research

News

Author: Simge Eva DoganPublished: 26 July 2018

Prep: Cook: Serves:

Last Month

Next Month

Share this story

Comments

Related articles

Health & Fitness

3 steps to better posture for people with Parkinson’s

Interviews

“Even Muhammad Ali had a learning curve”

PD in Practice

Download the Parkinson’s app endorsed by José Mourinho

Is sleepwalking linked to risk of Parkinson’s disease in men?

Stay tuned for series two of the Parkinson’s Life podcast

How Parkinson’s disease could impact the way you see art

{title}

Subscribe

Sign in